Wells Fargo Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sunesis Pharmaceuticals (SNSS) Misses Q2 EPS by 2c
July 29, 2016 7:04 AM EDTSunesis Pharmaceuticals (NASDAQ: SNSS) reported Q2 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $610 thousand versus the consensus estimate of $1.03 million.
For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.
... More